NAYA Biosciences (NAYA) - Long-Term Debt to Capital

International conflicts are hindering global scientific partnerships and biomaterial logistics for NAYA Biosciences (NAYA). This price chart illustrates the dynamics of NAYA Biosciences (NAYA), whose financial stability is constrained by the depletion of reserves in the absence of profit. Risks are amplified by the fierce competition for capital in the biotech sector, where failed tests can wipe out asset values, and the current indicator stands at 2.76.

The innovative oncology pipeline of NAYA Biosciences (NAYA) requires colossal investments to overcome early-stage development. The long-term debt-to-equity ratio is calculated as the ratio of liabilities with a maturity of over one year to equity. This chart reflects the extent of the issuer's reliance on debt financing. In the absence of revenue, low values minimize the risk of a liquidity gap, which is critical for maintaining the company's financial independence.